Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B

Abstract

In patients with HBeAg-negative chronic hepatitis B, the benefits achieved from 48 weeks of adefovir dipivoxil were lost when treatment was discontinued. In patients treated for 144 weeks, benefits were maintained, with infrequent emergence of viral resistance.